share_log
Moomoo 24/7 ·  Mar 14 09:47
Nuvectis Pharma Announced 33% Response Rate And 100% Disease Control Rate Observed In Patients Evaluated For Efficacy From The NXP800 Phase 1b Clinical Trial In Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment